Gaithersburg, Maryland, September. 15th 2023 /PRNewswire/ — YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”) is a company dedicated to discovering, developing, manufacturing and delivering next-generation vaccines and therapeutics , a global biopharmaceutical company targeting infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has granted the company a patent for PIKA YS-HBV-002, an immunotherapy vaccine designed to treat chronic hepatitis B virus ( “HBV”) infected patients. YS Biopharma expects to submit an Investigational New Drug (IND) application in 2024 and initiate clinical development of PIKA YS-HBV-002 as a novel immunotherapy for the treatment of chronic HBV infection.
The American Liver Foundation estimates that 850,000 to 2.2 million people in the United States have chronic hepatitis B virus infection. USA. According to the European Association for the Study of the Liver, nearly 2 billion people worldwide are hepatitis B carriers, and approximately 400 million people suffer from chronic hepatitis B virus infection. Infected people are at increased risk of cirrhosis, liver failure, and liver cancer, with 15%-40% of people with chronic hepatitis B having one or more of these conditions. Chronic hepatitis B virus infection occurs in both developing and developed countries and constitutes a major unresolved public health threat. Currently, existing treatment modalities have limited efficacy, and a cure for chronic hepatitis B has not yet been developed.
Unlike traditional preventive hepatitis B vaccines, which are administered to healthy individuals, PIKA YS-HBV-002 targets patients who already have chronic hepatitis B infection and are seeking effective treatment. PIKA YS-HBV-002 is developed based on YS Biopharma’s proprietary PIKA immune modulation technology and combines multiple HBV antigens. PIKA YS-HBV-002 has the potential to activate and re-establish the immune response needed in patients to eradicate HBV infection. In clinical settings, PIKA technology has shown great potential to activate both innate and adaptive immune responses in humans. In recent years, as people’s understanding of chronic hepatitis B has deepened, immune-based intervention has become an important strategy for the development of new treatments for chronic hepatitis B. of Underlying diseases and advances in immune technology.
gentlemen. Zhang YiProject Lead for the PIKA YS-HBV-002 Program and Chairman of the Board of Directors of YS Biopharma commented: “We are pleased to strengthen our strong intellectual property franchise by adding another important patent to our portfolio. This latest patent This patent underscores our dedication to innovation and our commitment to providing more treatment options to patients around the world. Our PIKA YS-HBV-002 vaccine has the potential to advance the fight against chronic HBV infection, a very important future medical needs addressed USA and around the globe. This clinical drug candidate is based on progress across multiple components of preclinical and clinical studies, and we are now focused on advancing it into clinical trials. “
About YS Biopharmaceuticals
YS Biopharma is a global biopharmaceutical company discovering, developing, manufacturing and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. It developed proprietary PIKA® Immunomodulation technology platform and next-generation biologics for the prevention and treatment of rabies, coronavirus, hepatitis B, influenza, shingles and other viral infections. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines deep local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical or current fact are forward-looking statements, including, without limitation, statements regarding YS Biopharma’s expected growth, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma the ability to find and retain talent, and YS Biopharma’s cash position following the closing of the business combination. Forward-looking statements can be identified by the use of words such as “estimates,” “plans,” “projects” and other words. , “predict,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “goal” or other similar expressions that predict or indicate future events or trends, or are not statements historical events. These statements are based on various assumptions, whether or not identified in this release, and the current expectations of YS Biopharma’s management and are not predictions of current performance.
These statements involve risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that each forward-looking statement contained in this press release has a reasonable basis, YS Biopharma cautions you that these statements are based on a combination of currently known facts and factors as well as projections of the future. It is inherently uncertain. In addition, risks and uncertainties related to the proposed business combination are described in the final prospectus and other documents YS Biopharma files with the SEC from time to time. These documents may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to identify the expected benefits of the business combination, costs associated with the transaction, the impact of the global COVID-19 pandemic, risks arising from the completion of the transaction, the outcome of any potential litigation , governmental or regulatory proceedings, sales performance of marketed vaccine products and clinical trial development results of YS Biopharma’s product candidates, disruption of transactions to current plans and operations of Biopharma, and other risks and uncertainties, including YS Biopharma’s filings with the SEC risks and uncertainties involved. There may be other risks that YS Biopharma is not currently aware of or that YS Biopharma currently considers to be immaterial, which could also cause actual results to differ from those contained in the forward-looking statements. Given that these forward-looking statements are subject to significant uncertainties, nothing contained in this press release should be deemed to be a representation by any person that the forward-looking statements described herein will be achieved or that any anticipated results from such forward-looking statements will be achieved. Look for statements. The search for statements will come true. The forward-looking statements in this press release represent YS Biopharma’s views as of the date of this press release. Subsequent events and developments may cause these views to change. However, while YS Biopharma may update these forward-looking statements in the future, it currently has no intention to do so except to the extent required by applicable law. Accordingly, you should not rely on these forward-looking statements as representing YS Biopharma’s views as of any date following the date of this press release. YS Biopharma disclaims any obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact
Alisa Lee
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR LLC
Phone: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/ys-biopharma-granted-patent-in-the-us-for-immunotherapy-targeting-chronic-hepatitis-b-virus-infection – 301928926.html
Source: Yisheng Biopharmaceutical Co., Ltd.